Search

Displaying results 2381 - 2390 of 6196 in total
  1. Target

    Acyl carrier protein

    go.drugbank.com/bio_entities/BE0001948
    TargetSalmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)

    Carrier of the growing fatty acid chain in fatty acid biosynthesis.

    Synonyms: CAF
  2. Target

    Acyl carrier protein

    go.drugbank.com/bio_entities/BE0004133
    TargetEscherichia coli (strain K12)

    Carrier of the growing fatty acid chain in fatty acid biosynthesis.

    Synonyms: CAF
  3. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  4. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment

    International brands: A Gan Ding
  5. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.

  6. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  7. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … [A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A.

  8. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

  9. Drug

    Typhoid Vaccine Live

    go.drugbank.com/drugs/DB11050
    ApprovedInvestigational

    The vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.

  10. Indication

    BCG-unresponsive non-muscle invasive bladder cancer

    go.drugbank.com/conditions/DBCOND0153568
    Drugs: Inbakicept · Nogapendekin alfa
    Synonyms: Ca bladder, Bladder Ca